For UK pharmaceutical and life sciences leaders
Your NHS focus is leaving millions in private prescription revenue unclaimed
As waiting lists push patients toward private consultants, most pharma companies have no private pricing, no engagement model, and no visibility of who is prescribing. That gap compounds every quarter.
Two minutes. Solva follows up with specific private market strategy options.
- Absence from private hospital formularies, leading to missed prescribing opportunities.
- Lack of clear pricing and reimbursement pathways for private patients.
- Limited engagement with independent prescribers and private healthcare networks.
- Inability to track or measure private market performance effectively.
- Inefficient resource allocation due to a lack of clear private market strategy.
- Missed opportunities for product uptake and market penetration in a growing sector.
- Significant loss of potential revenue from a rapidly expanding market segment.
- Competitors gaining market share in the private sector due to proactive strategies.
- Perception as a company solely focused on the NHS, potentially limiting appeal to private healthcare providers and patients.
- Missed opportunities to establish brand presence and trust within the private healthcare ecosystem.
The UK private retail prescription market experienced a growth rate of approximately 180% between 2023 and 2024, significantly outgrowing the total retail market by more than tenfold. (IQVIA, 2025)
Frequently asked questions
Why does this problem persist?
The UK private prescription market is growing as NHS waiting lists drive patients to private consultants. Many pharma companies have no private market strategy, no private pricing, and no engagement with private hospital formularies or independent prescribers. This is an increasingly significant missed opportunity.
What is the cost of leaving it unaddressed?
The private retail prescription market in the UK represents approximately 10% of the total retail prescription expenditure. For a £50m NHS medicine, this represents £4m–£6m in untapped revenue. (IQVIA, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.